Name: Avecho Biotechnology (AVE) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

AVE

Pharmaceuticals, Biotechnology & Life Sciences

Avecho Biotechnology

Short interest: 0.00%; −0.12 pp 30d; as of 10 Feb 2025
Reported shorts: 29.6K
Shares on issue: 3.169B

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Avecho Biotechnology

Avecho Biotechnology is an Australian innovation-led biotechnology company focused on developing and commercializing human health, animal health, and personal care products. They utilize their proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM) to enhance the solubility and adsorption of drugs and nutrients. Avecho aims to create new market opportunities for healthcare leaders by differentiating their products.

Company profile →

Avecho Biotechnology (ASX:AVE) has 0.00% of its shares on issue reported as short positions as of 10 Feb 2025, or about 29,568 shares. Over the past 30 days that figure has fallen 0.12 percentage points, and over 90 days it has fallen 0.12 percentage points. Its highest recorded short interest was 0.55% in November 2010. AVE is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads AVE today

Zanger BreakoutNot a candidate
CAN SLIMWatchScore 15rank 843 of 1541
Minervini Trend TemplateWatchScore 36rank 456 of 1716
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 23rank 640 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

AVE fundamentals

In the half year to 30 Jun 2026, Avecho Biotechnology (ASX:AVE) recorded a net loss after tax of A$1.9M. Year-on-year growth: revenue +9.9% (FY). Net margin −493.6%, return on equity −151.7% (TTM). Figures are in AUD, the company's reporting currency; source: Company filing (extracted) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →